Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer.

ABSTRACT:

Background

Non-small cell lung cancer (NSCLC) is one of the most prevalent causes of cancer-related death worldwide. Recently, there are many important medical advancements on NSCLC, such as therapies based on tyrosine kinase inhibitors and immune checkpoint inhibitors. Most of these therapies require tumor molecular testing for selecting patients who would benefit most from them. As invasive biopsy is highly risky, NSCLC molecular testing based on liquid biopsy has received more and more attention recently.

Objective

We aimed to introduce liquid biopsy and its potential clinical applications in NSCLC patients, including cancer diagnosis, treatment plan prioritization, minimal residual disease detection, and dynamic monitoring on the response to cancer treatment.

Method</

SUBMITTER: Yang J 

PROVIDER: S-EPMC8375502 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature